Загрузка...
Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge
Tyrosine kinase inhibitors (TKIs) are highly effective agents for the treatment of lung cancer which harbors activated gene mutation. However, for patients with failure of TKI, TKI re-treatment beyond progression (TRBP) is still a potential option that has been proven by many literatures. In this re...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Pioneer Bioscience Publishing Company
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4073393/ https://ncbi.nlm.nih.gov/pubmed/24976979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2014.04.36 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|